20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
Although at the moment we do not report any technological gaps, we expect an improvement in the prediction precision, as a consequence of the integration of the microbiome data analysis with the data on genomic stability, of the immune system imbalance, and of the chronic inflammation levels. The AI that will integrate the MICROBALANCE results with anamnestic data and with the results of the other HELIXAFE tests will be developed in WP1; it will give our customers a completely automated, reliable output, and will get automatically updated and fine-tuned by the fees of new information and data. In WP2 we will give validation to our AI ability to integrate the MICROBALANCE results with anamnestic data and with the results of the other HELIXAFE tests to profile an individual’s colorectal cancer risk.
